TreeWAS – Variant ID: rs2621322

Hospitalization Episode Statistics (HES)

Self-Reported Statistics (SRS)

Hierarchical visualisation How to interpret this figure?

Click here to show this figure without filtering.

Click on a node to zoom (except terminal nodes).

Download this figure in format

Results table

Term	Risk posterior probability	No effect posterior probability	Protective posterior probability
E10.9 Without complications	0.000	0.000	1.000
K90.0 Coeliac disease	0.000	0.000	1.000
L40.9 Psoriasis, unspecified	1.000	0.000	0.000
L40.5 Arthropathic psoriasis	1.000	0.000	0.000
E10 Insulin-dependent diabetes mellitus	0.000	0.000	1.000
I25 Chronic ischaemic heart disease	1.000	0.000	0.000
I20-I25 Ischaemic heart diseases	1.000	0.000	0.000
L40 Psoriasis	1.000	0.000	0.000
C82.9 Follicular non-Hodgkin's lymphoma, unspecified	1.000	0.000	0.000
I21 Acute myocardial infarction	1.000	0.000	0.000
I21.9 Acute myocardial infarction, unspecified	1.000	0.000	0.000
E10.3 With ophthalmic complications	0.000	0.001	0.999
T42 Poisoning by antiepileptic, sedative-hypnotic and anti-Parkinsonism drugs	0.998	0.002	0.000
T36-T50 Poisoning by drugs, medicaments and biological substances	0.998	0.002	0.000
M07.39 Other psoriatic arthropathies (Site unspecified)	0.997	0.003	0.000
C82 Follicular [nodular] non-Hodgkin's lymphoma	0.997	0.003	0.000
I25.9 Chronic ischaemic heart disease, unspecified	0.996	0.004	0.000
M07.3 Other psoriatic arthropathies	0.995	0.005	0.000
I25.1 Atherosclerotic heart disease	0.994	0.006	0.000
T50 Poisoning by diuretics and other and unspecified drugs, medicaments and biological substances	0.994	0.006	0.000
M07.30 Other psoriatic arthropathies (Multiple sites)	0.992	0.008	0.000
E10.1 With ketoacidosis	0.000	0.009	0.991
I25.2 Old myocardial infarction	0.990	0.010	0.000
T42.4 Benzodiazepines	0.990	0.010	0.000
T50.9 Other and unspecified drugs, medicaments and biological substances	0.989	0.011	0.000
T42.6 Other antiepileptic and sedative-hypnotic drugs	0.989	0.011	0.000
I25.8 Other forms of chronic ischaemic heart disease	0.986	0.014	0.000
I24 Other acute ischaemic heart diseases	0.971	0.029	0.000
J45.9 Asthma, unspecified	0.000	0.033	0.967
D86 Sarcoidosis	0.000	0.041	0.959
D86.9 Sarcoidosis, unspecified	0.000	0.042	0.958
I20 Angina pectoris	0.955	0.045	0.000
D80-D89 Certain disorders involving the immune mechanism	0.000	0.049	0.951
Chapter III Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	0.000	0.051	0.949
C82.0 Small cleaved cell, follicular	0.948	0.052	0.000
I24.9 Acute ischaemic heart disease, unspecified	0.947	0.053	0.000
D65-D69 Coagulation defects, purpura and other haemorrhagic conditions	0.000	0.055	0.945
T43 Poisoning by psychotropic drugs, not elsewhere classified	0.941	0.059	0.000
D69 Purpura and other haemorrhagic conditions	0.000	0.060	0.940
D50-D53 Nutritional anaemias	0.000	0.061	0.939
D86.0 Sarcoidosis of lung	0.000	0.067	0.933
D69.6 Thrombocytopenia, unspecified	0.000	0.067	0.933
E10.4 With neurological complications	0.000	0.072	0.928
D51 Vitamin B12 deficiency anaemia	0.000	0.073	0.927
D51.0 Vitamin B12 deficiency anaemia due to intrinsic factor deficiency	0.000	0.084	0.916
I20.0 Unstable angina	0.902	0.098	0.000
I21.4 Acute subendocardial myocardial infarction	0.876	0.124	0.000
M07.36 Other psoriatic arthropathies (Lower leg)	0.871	0.129	0.000
I25.3 Aneurysm of heart	0.871	0.129	0.000
E10.0 With coma	0.000	0.132	0.868
C82.2 Large cell, follicular	0.867	0.133	0.000
I21.1 Acute transmural myocardial infarction of inferior wall	0.863	0.137	0.000
I23 Certain current complications following acute myocardial infarction	0.863	0.137	0.000
T47 Poisoning by agents primarily affecting gastro-intestinal system	0.856	0.144	0.000
I20.1 Angina pectoris with documented spasm	0.856	0.144	0.000
T43.2 Other and unspecified antidepressants	0.855	0.145	0.000
T46 Poisoning by agents primarily affecting the cardiovascular system	0.853	0.147	0.000
T44 Poisoning by drugs primarily affecting the autonomic nervous system	0.848	0.152	0.000
L40.1 Generalised pustular psoriasis	0.847	0.153	0.000
T38 Poisoning by hormones and their synthetic substitutes and antagonists, not elsewhere classified	0.845	0.155	0.000
C82.3 Follicular lymphoma grade IIIa	0.840	0.160	0.000
C81-C96 Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue	0.840	0.160	0.000
M07.37 Other psoriatic arthropathies (Ankle and foot)	0.838	0.162	0.000
C85 Other and unspecified types of non-Hodgkin's lymphoma	0.834	0.166	0.000
E10.8 With unspecified complications	0.000	0.172	0.828
I21.2 Acute transmural myocardial infarction of other sites	0.827	0.173	0.000
C82.7 Other types of follicular non-Hodgkin's lymphoma	0.825	0.175	0.000
T43.5 Other and unspecified antipsychotics and neuroleptics	0.814	0.186	0.000
T42.7 Antiepileptic and sedative-hypnotic drugs, unspecified	0.813	0.187	0.000
T50.2 Carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics	0.809	0.191	0.000
L40.4 Guttate psoriasis	0.808	0.192	0.000
C85.1 B-cell lymphoma, unspecified	0.805	0.195	0.000
D69.3 Idiopathic thrombocytopenic purpura	0.000	0.196	0.804
E10.2 With renal complications	0.000	0.196	0.804
I25.5 Ischaemic cardiomyopathy	0.799	0.201	0.000
T43.3 Phenothiazine antipsychotics and neuroleptics	0.798	0.202	0.000
C85.9 Non-Hodgkin's lymphoma, unspecified type	0.795	0.205	0.000
C82.1 Mixed small cleaved and large cell, follicular	0.792	0.208	0.000
D86.8 Sarcoidosis of other and combined sites	0.000	0.208	0.792
L40-L45 Papulosquamous disorders	0.791	0.209	0.000
D68 Other coagulation defects	0.000	0.212	0.788
I25.0 Atherosclerotic cardiovascular disease, so described	0.784	0.216	0.000
T42.8 Anti-Parkinsonism drugs and other central muscle-tone depressants	0.781	0.219	0.000
E10.6 With other specified complications	0.000	0.221	0.779
M07.34 Other psoriatic arthropathies (Hand)	0.775	0.225	0.000
T45 Poisoning by primarily systemic and haematological agents, not elsewhere classified	0.773	0.227	0.000
C82.4 Follicular lymphoma grade IIIb	0.770	0.230	0.000
I24.8 Other forms of acute ischaemic heart disease	0.769	0.231	0.000
T42.1 Iminostilbenes	0.765	0.235	0.000
D52 Folate deficiency anaemia	0.000	0.235	0.765
T46.6 Antihyperlipidaemic and antiarteriosclerotic drugs	0.764	0.236	0.000
D69.5 Secondary thrombocytopenia	0.000	0.244	0.756
T47.1 Other antacids and anti-gastric-secretion drugs	0.755	0.245	0.000
D89 Other disorders involving the immune mechanism, not elsewhere classified	0.000	0.246	0.754
D50 Iron deficiency anaemia	0.000	0.247	0.753
I23.2 Ventricular septal defect as current complication following acute myocardial infarction	0.742	0.258	0.000
T36 Poisoning by systemic antibiotics	0.736	0.264	0.000
T42.0 Hydantoin derivatives	0.735	0.265	0.000
E78.0 Pure hypercholesterolaemia	0.734	0.266	0.000
J45 Asthma	0.000	0.272	0.728
L40.0 Psoriasis vulgaris	0.727	0.273	0.000
D69.4 Other primary thrombocytopenia	0.000	0.275	0.725
D51.9 Vitamin B12 deficiency anaemia, unspecified	0.000	0.281	0.719
E10.7 With multiple complications	0.000	0.283	0.717
I25.6 Silent myocardial ischaemia	0.717	0.283	0.000
L40.3 Pustulosis palmaris et plantaris	0.717	0.283	0.000
L40.2 Acrodermatitis continua	0.717	0.283	0.000
I21.X Presumed acute myicardial infaction (unconfirmed)	0.717	0.283	0.000
T42.5 Mixed antiepileptics, not elsewhere classified	0.716	0.284	0.000
T42.3 Barbiturates	0.716	0.284	0.000
T42.2 Succinimides and oxazolidinediones	0.716	0.284	0.000
T49 Poisoning by topical agents primarily affecting skin and mucous membrane and by ophthalmological, otorhinolarygological and dental drugs	0.715	0.284	0.000
T48 Poisoning by agents primarily acting on smooth and skeletal muscles and the respiratory system	0.715	0.284	0.000
T41 Poisoning by anaesthetics and therapeutic gases	0.715	0.284	0.000
T37 Poisoning by other systemic anti-infectives and antiparasitics	0.715	0.284	0.000
C82.6 Cutaneous follicle centre lymphoma	0.714	0.285	0.000
C82.5 Diffuse follicle centre lymphoma	0.714	0.285	0.000
M07.38 Other psoriatic arthropathies (Other)	0.714	0.286	0.000
M07.35 Other psoriatic arthropathies (Pelvic region and thigh)	0.714	0.286	0.000
M07.33 Other psoriatic arthropathies (Forearm)	0.714	0.286	0.000
M07.32 Other psoriatic arthropathies (Upper arm)	0.714	0.286	0.000
M07.31 Other psoriatic arthropathies (Shoulder region)	0.714	0.286	0.000
T50.8 Diagnostic agents	0.712	0.287	0.000
T50.7 Analeptics and opioid receptor antagonists	0.712	0.287	0.000
T50.6 Antidotes and chelating agents, not elsewhere classified	0.712	0.287	0.000
T50.5 Appetite depressants	0.712	0.287	0.000
T50.3 Electrolytic, caloric and water-balance agents	0.712	0.287	0.000
T50.1 Loop [high-ceiling] diuretics	0.712	0.287	0.000
T50.0 Mineralocorticoids and their antagonists	0.712	0.287	0.000
L40.8 Other psoriasis	0.712	0.288	0.000
T50.4 Drugs affecting uric acid metabolism	0.709	0.291	0.000
I20.9 Angina pectoris, unspecified	0.707	0.293	0.000
D69.0 Allergic purpura	0.000	0.293	0.707
T38.1 Thyroid hormones and substitutes	0.706	0.294	0.000
I24.1 Dressler's syndrome	0.696	0.304	0.000
I22 Subsequent myocardial infarction	0.694	0.306	0.000
D66 Hereditary factor VIII deficiency	0.000	0.306	0.693
D50.9 Iron deficiency anaemia, unspecified	0.000	0.306	0.694
D86.2 Sarcoidosis of lung with sarcoidosis of lymph nodes	0.000	0.312	0.688
D82 Immunodeficiency associated with other major defects	0.000	0.318	0.682
D81 Combined immunodeficiencies	0.000	0.318	0.682
J45.0 Predominantly allergic asthma	0.000	0.320	0.680
D67 Hereditary factor IX deficiency	0.000	0.322	0.678
D65 Disseminated intravascular coagulation [defibrination syndrome]	0.000	0.322	0.678
T43.9 Psychotropic drug, unspecified	0.674	0.325	0.000
T43.8 Other psychotropic drugs, not elsewhere classified	0.674	0.325	0.000
T43.1 Monoamine-oxidase-inhibitor antidepressants	0.674	0.325	0.000
D68.9 Coagulation defect, unspecified	0.000	0.326	0.674
D69.8 Other specified haemorrhagic conditions	0.000	0.326	0.674
D55-D59 Haemolytic anaemias	0.000	0.329	0.671
D68.0 Von Willebrand's disease	0.000	0.331	0.669
C44 Other malignant neoplasms of skin	0.667	0.333	0.000
T44.7 Beta-Adrenoreceeptor antagonists, not elsewhere classified	0.666	0.334	0.000
I23.8 Other current complications following acute myocardial infarction	0.665	0.335	0.000
T44.9 Other and unspecified drugs primarily affecting the nervous system	0.664	0.335	0.000
D51.8 Other vitamin B12 deficiency anaemias	0.000	0.336	0.664
D51.3 Other dietary vitamin B12 deficiency anaemia	0.000	0.336	0.664
D51.2 Transcobalamin II deficiency	0.000	0.336	0.664
D51.1 Vitamin B12 deficiency anaemia due to selective vitamin B12 malabsorption with proteinuria	0.000	0.336	0.664
D69.9 Haemorrhagic condition, unspecified	0.000	0.336	0.664
T44.3 Other parasympatholytics [anticholinergics and antimuscarines] and spasmolytics, not elsewhere classified	0.663	0.337	0.000
T38.3 Insulin and oral hypoglycaemic [antidiabetic] drugs	0.658	0.342	0.000
L42 Pityriasis rosea	0.654	0.346	0.000
I24.0 Coronary thrombosis not resulting in myocardial infarction	0.649	0.351	0.000
C95 Leukaemia of unspecified cell type	0.648	0.352	0.000
T43.4 Butyrophenone and thioxanthene neuroleptics	0.647	0.353	0.000
E78 Disorders of lipoprotein metabolism and other lipidaemias	0.645	0.355	0.000
M07 Psoriatic and enteropathic arthropathies	0.645	0.355	0.000
D68.8 Other specified coagulation defects	0.000	0.356	0.644
C44.2 Skin of ear and external auricular canal	0.642	0.358	0.000
D86.1 Sarcoidosis of lymph nodes	0.000	0.359	0.641
D52.9 Folate deficiency anaemia, unspecified	0.000	0.360	0.640
E10.5 With peripheral circulatory complications	0.000	0.361	0.639
I21.3 Acute transmural myocardial infarction of unspecified site	0.636	0.364	0.000
C44.3 Skin of other and unspecified parts of face	0.636	0.364	0.000
C44.4 Skin of scalp and neck	0.635	0.365	0.000
D86.3 Sarcoidosis of skin	0.000	0.370	0.630
T45.0 Antiallergic and antiemetic drugs	0.630	0.370	0.000
C44.7 Skin of lower limb, including hip	0.626	0.374	0.000
C43-C44 Melanoma and other malignant neoplasms of skin	0.624	0.376	0.000
D83 Common variable immunodeficiency	0.000	0.380	0.620
I23.6 Thrombosis of atrium, auricular appendage and ventricle as current complications following acute myocardial infarction	0.619	0.381	0.000
I23.5 Rupture of papillary muscle as current complication following acute myocardial infarction	0.619	0.381	0.000
I23.4 Rupture of chordae tendineae as current complication following acute myocardial infarction	0.619	0.381	0.000
I23.3 Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction	0.619	0.381	0.000
I23.1 Atrial septal defect as current complication following acute myocardial infarction	0.619	0.381	0.000
I23.0 Haemopericardium as current complication following acute myocardial infarction	0.619	0.381	0.000
D84 Other immunodeficiencies	0.000	0.384	0.615
D68.5 Primary Thrombophilia	0.000	0.385	0.615
T47.9 Agent primarily affecting the gastro-intestinal system, unspecified	0.614	0.386	0.000
T47.8 Other agents primarily affecting the gastro-intestinal system	0.614	0.386	0.000
T47.7 Emetics	0.614	0.386	0.000
T47.6 Antidiarrhoeal drugs	0.614	0.386	0.000
T47.5 Digestants	0.614	0.386	0.000
T47.4 Other laxatives	0.614	0.386	0.000
T47.3 Saline and osmotic laxatives	0.614	0.386	0.000
T47.2 Stimulant laxatives	0.614	0.386	0.000
T47.0 Histamine H(2)-receptor antagonists	0.614	0.386	0.000
T46.9 Other and unspecified agents primarily affecting the cardiovascular system	0.612	0.388	0.000
T46.8 Antivaricose drugs, including sclerosing agents	0.612	0.388	0.000
T46.7 Peripheral vasodilators	0.612	0.388	0.000
T46.5 Other antihypertensive drugs, not elsewhere classified	0.612	0.388	0.000
T46.3 Coronary vasodilators, not elsewhere classified	0.612	0.388	0.000
T46.2 Other antidysrhythmic drugs, not elsewhere classified	0.612	0.388	0.000
T46.0 Cardiac-stimulant glycosides and drugs of similar action	0.612	0.388	0.000
L43 Lichen planus	0.610	0.390	0.000
E78.5 Hyperlipidaemia, unspecified	0.610	0.390	0.000
T44.8 Centrally acting and afrenergic-neuron-blocking agents, not elsewhere classified	0.608	0.392	0.000
T44.6 Alpha-Adrenoreceeptor antagonists, not elsewhere classified	0.608	0.392	0.000
T44.5 Predominantly Beta-adrenoreceptor agonists, not elsewhere classified	0.608	0.392	0.000
T44.4 Predominantly Alpha-adrenoreceptor agonists, not elsewhere classified	0.608	0.392	0.000
T44.2 Ganglionic blocking drugs, not elsewhere classified	0.608	0.392	0.000
T44.1 Other parasympathomimetics [cholinergics]	0.608	0.392	0.000
T44.0 Anticholinesterase agents	0.608	0.392	0.000
D89.2 Hypergammaglobulinaemia, unspecified	0.000	0.393	0.607
C90 Multiple myeloma and malignant plasma cell neoplasms	0.607	0.393	0.000
T46.1 Calcium-channel blockers	0.606	0.393	0.000
T38.9 Other and unspecified hormone antagonists	0.606	0.394	0.000
T38.8 Other and unspecified hormones and their synthetic substitutes	0.606	0.394	0.000
T38.7 Androgens and anabolic congeners	0.606	0.394	0.000
T38.6 Antigonadotrophins. antioestrogens, antiandrogens, not elsewhere classified	0.606	0.394	0.000
T38.5 Other oestrogens and progestogens	0.606	0.394	0.000
T38.4 Oral contraceptives	0.606	0.394	0.000
T38.2 Antithyroid drugs	0.606	0.394	0.000
T38.0 Glucocorticoids and synthetic analogues	0.606	0.394	0.000
Chapter IV Endocrine, nutritional and metabolic diseases	0.302	0.394	0.303
T43.0 Tricyclic and tetracyclic antidepressants	0.603	0.397	0.000
C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	0.602	0.398	0.000
C94 Other leukaemias of specified cell type	0.602	0.398	0.000
C86 Other specified types of T/NK-cell lymphoma	0.602	0.398	0.000
C85.2 Mediastinal (thymic) large B-cell lymphoma	0.598	0.402	0.000
C85.0 Lymphosarcoma	0.598	0.402	0.000
Chapter II Neoplasms	0.595	0.405	0.000
C85.7 Other specified types of non-Hodgkin's lymphoma	0.591	0.409	0.000
D53 Other nutritional anaemias	0.000	0.410	0.590
E78.2 Mixed hyperlipidaemia	0.590	0.410	0.000
T43.6 Psychostimulants with abuse potential	0.586	0.413	0.000
T45.5 Anticoagulants	0.586	0.414	0.000
I22.1 Subsequent myocardial infarction of inferior wall	0.584	0.416	0.000
D69.2 Other nonthrombocytopenic purpura	0.000	0.421	0.579
T46.4 Angiotensin-converting-enzyme inhibitors	0.579	0.421	0.000
C93 Monocytic leukaemia	0.572	0.428	0.000
I22.0 Subsequent myocardial infarction of anterior wall	0.568	0.432	0.000
L44 Other papulosquamous disorders	0.567	0.433	0.000
L41 Parapsoriasis	0.567	0.433	0.000
L45 Papulosquamous disorders in diseases classified elsewhere	0.567	0.433	0.000
D50.8 Other iron deficiency anaemias	0.000	0.435	0.565
D68.4 Acquired coagulation factor deficiency	0.000	0.435	0.565
D68.1 Hereditary factor XI deficiency	0.000	0.435	0.565
C73-C75 Malignant neoplasms of thyroid and other endocrine glands	0.563	0.437	0.000
D59 Acquired haemolytic anaemia	0.000	0.439	0.561
C44.9 Malignant neoplasm of skin, unspecified	0.560	0.440	0.000
T45.9 Primarily systemic and haematological agent, unspecified	0.554	0.446	0.000
T45.8 Other primarily systemic and haematological agents	0.554	0.446	0.000
T45.7 Anticoagulant antagonists, vitamin K and other coagulants	0.554	0.446	0.000
T45.6 Fibrinolysis-affecting drugs	0.554	0.446	0.000
T45.4 Iron and its compounds	0.554	0.446	0.000
T45.3 Enzymes, not elsewhere classified	0.554	0.446	0.000
I25.4 Coronary artery aneurysm	0.549	0.451	0.000
D89.9 Disorder involving the immune mechanism, unspecified	0.000	0.451	0.549
T36.0 Penicillins	0.548	0.452	0.000
D52.8 Other folate deficiency anaemias	0.000	0.452	0.548
D52.1 Drug-induced folate deficiency anaemia	0.000	0.452	0.548
D52.0 Dietary folate deficiency anaemia	0.000	0.452	0.548
T45.2 Vitamins, not elsewhere classified	0.545	0.454	0.000
D69.1 Qualitative platelet defects	0.000	0.459	0.540
D89.8 Other specified disorders involving the immune mechanism, not elsewhere classified	0.000	0.459	0.540
D89.3 Immune reconstitution syndrome	0.000	0.459	0.540
D89.0 Polyclonal hypergammaglobulinaemia	0.000	0.459	0.540
D50.1 Sideropenic dysphagia	0.000	0.460	0.540
D89.1 Cryoglobulinaemia	0.000	0.460	0.540
D68.3 Haemorrhagic disorder due to circulating anticoagulants	0.000	0.467	0.533
T36.9 Systemic antibiotic, unspecified	0.528	0.472	0.000
T36.8 Other systemic antibiotics	0.528	0.472	0.000
T36.7 Antifungal antibiotics, systemically used	0.528	0.472	0.000
T36.6 Rifamycins	0.528	0.472	0.000
T36.5 Aminoglycosides	0.528	0.472	0.000
T36.4 Tetracyclines	0.528	0.472	0.000
T36.3 Macrolides	0.528	0.472	0.000
T36.2 Chloramphenicol group	0.528	0.472	0.000
T36.1 Cefalosporins and other Beta-lactam antibiotics	0.528	0.472	0.000
C44.0 Skin of lip	0.527	0.473	0.000
J45.8 Mixed asthma	0.000	0.478	0.522
J45.1 Nonallergic asthma	0.000	0.478	0.522
C73 Malignant neoplasm of thyroid gland	0.519	0.481	0.000
E78.6 Lipoprotein deficiency	0.518	0.481	0.000
D80 Immunodeficiency with predominantly antibody defects	0.000	0.483	0.517
T37.9 Systemic anti-infective and antiparasitic, unspecified	0.513	0.487	0.000
T37.8 Other specified systemic anti-infectives and antiparasitics	0.513	0.487	0.000
T37.5 Antiviral drugs	0.513	0.487	0.000
T37.4 Anthelminthics	0.513	0.487	0.000
T37.3 Other antiprotozoal drugs	0.513	0.487	0.000
T37.2 Antimalarials and drugs acting on other blood protozoa	0.513	0.487	0.000
T37.1 Antimycobacterial drugs	0.513	0.487	0.000
T37.0 Sulphonamides	0.513	0.487	0.000
T41.5 Therapeutic gases	0.513	0.487	0.000
T41.4 Anaesthetic, unspecified	0.513	0.487	0.000
T41.3 Local anaesthetics	0.513	0.487	0.000
T41.2 Other and unspecified general anaesthetics	0.513	0.487	0.000
T41.1 Intravenous anaesthetics	0.513	0.487	0.000
T41.0 Inhaled anaesthetics	0.513	0.487	0.000
T48.7 Other and unspecified agents primarily acting on the respiratory system	0.513	0.487	0.000
T48.6 Antiasthmatics, not elsewhere classified	0.513	0.487	0.000
T48.5 Anti-common-cold drugs	0.513	0.487	0.000
T48.4 Expectorants	0.513	0.487	0.000
T48.3 Antitussives	0.513	0.487	0.000
T48.2 Other and unspecified agents primarily acting on muscles	0.513	0.487	0.000
T48.1 Skeletal muscle relaxants [neuromuscular blocking agents]	0.513	0.487	0.000
T48.0 Oxytocic drugs	0.513	0.487	0.000
T49.9 Topical agent, unspecified	0.513	0.487	0.000
T49.8 Other topical agents	0.513	0.487	0.000
T49.7 Dental drugs, topically applied	0.513	0.487	0.000
T49.6 Otorhinolaryngological drugs and preparations	0.513	0.487	0.000
T49.5 Ophthalmological drugs and preparations	0.513	0.487	0.000
T49.4 Keratolytics, keratoplastics and other hair treatment drugs and preparations	0.513	0.487	0.000
T49.3 Emollients, demulcents and protectants	0.513	0.487	0.000
T49.2 Local astringents and local detergents	0.513	0.487	0.000
T49.1 Antipruritics	0.513	0.487	0.000
T49.0 Local antifungal, anti-infective and anti-inflammatory drugs, not elsewhere classified	0.513	0.487	0.000
C95.9 Leukaemia, unspecified	0.511	0.489	0.000
C84 Peripheral and cutaneous T-cell lymphomas	0.509	0.491	0.000
L43.9 Lichen planus, unspecified	0.501	0.499	0.000
C44.5 Skin of trunk	0.498	0.502	0.000
T45.1 Antineoplastic and immunosuppressive drugs	0.496	0.504	0.000
E10-E14 Diabetes mellitus	0.122	0.506	0.372
T40 Poisoning by narcotics and psychodysleptics [hallucinogens]	0.493	0.506	0.000
D59.1 Other autoimmune haemolytic anaemias	0.000	0.508	0.492
C88 Malignant immunoproliferative diseases	0.491	0.508	0.000
D81.9 Combined immunodeficiency, unspecified	0.000	0.511	0.489
D81.8 Other combined immunodeficiencies	0.000	0.511	0.489
D81.7 Major histocompatibility complex class II deficiency	0.000	0.511	0.489
D81.6 Major histocompatibility complex class I deficiency	0.000	0.511	0.489
D81.5 Purine nucleoside phosphorylase [PNP] deficiency	0.000	0.511	0.489
D81.4 Nezelof's syndrome	0.000	0.511	0.489
D81.3 Adenosine deaminase [ADA] deficiency	0.000	0.511	0.489
D81.2 Severe combined immunodeficiency [SCID] with low or normal B-cell numbers	0.000	0.511	0.489
D81.1 Severe combined immunodeficiency [SCID] with low T- and B-cell numbers	0.000	0.511	0.489
D81.0 Severe combined immunodeficiency [SCID] with reticular dysgenesis	0.000	0.511	0.489
D82.9 Immunodeficiency associated with major defect, unspecified	0.000	0.511	0.489
D82.8 Immunodeficiency associated with other specified major defects	0.000	0.511	0.489
D82.4 Hyperimmunoglobulin E [IgE] syndrome	0.000	0.511	0.489
D82.3 Immunodeficiency following hereditary defective response to Epstein-Barr virus	0.000	0.511	0.489
D82.2 Immunodeficiency with short-limbed stature	0.000	0.511	0.489
D82.1 Di George's syndrome	0.000	0.511	0.489
D82.0 Wiskott-Aldrich syndrome	0.000	0.511	0.489
C00-C14 Malignant neoplasms of lip, oral cavity and pharynx	0.488	0.512	0.000
Chapter XII Diseases of the skin and subcutaneous tissue	0.486	0.514	0.000
T39 Poisoning by nonopioid analgesics, antipyretics and antirheumatics	0.484	0.516	0.000
D57 Sickle-cell disorders	0.000	0.519	0.481
D55 Anaemia due to enzyme disorders	0.000	0.519	0.481
F40-F48 Neurotic, stress-related and somatoform disorders	0.480	0.520	0.000
F41.0 Panic disorder [episodic paroxysmal anxiety]	0.479	0.521	0.000
C44.8 Overlapping lesion of skin	0.479	0.521	0.000
C92 Myeloid leukaemia	0.478	0.522	0.000
F41 Other anxiety disorders	0.477	0.523	0.000
C74 Malignant neoplasm of adrenal gland	0.473	0.527	0.000
K90 Intestinal malabsorption	0.002	0.529	0.469
L55-L59 Radiation-related disorders of the skin and subcutaneous tissue	0.469	0.531	0.000
Chapter V Mental and behavioural disorders	0.467	0.533	0.000
C95.7 Other leukaemia of unspecified cell type	0.465	0.535	0.000
C95.2 Subacute leukaemia of unspecified cell type	0.465	0.535	0.000
C95.1 Chronic leukaemia of unspecified cell type	0.465	0.535	0.000
C95.0 Acute leukaemia of unspecified cell type	0.465	0.535	0.000
D68.6 Other Thrombophilia	0.000	0.536	0.464
E78.3 Hyperchylomicronaemia	0.463	0.537	0.000
M07.6 Other enteropathic arthropathies	0.462	0.537	0.000
M07.5 Arthropathy in ulcerative colitis	0.462	0.537	0.000
M07.4 Arthropathy in Crohn's disease [regional enteritis]	0.462	0.537	0.000
M07.2 Psoriatic spondylitis	0.462	0.537	0.000
M07.1 Arthritis mutilans	0.462	0.537	0.000
M07.0 Distal interphalangeal psoriatic arthropathy	0.462	0.537	0.000
C97-C97 Malignant neoplasms of independent (primary) multiple sites	0.462	0.538	0.000
C02 Malignant neoplasm of other and unspecified parts of tongue	0.461	0.539	0.000
C90.0 Multiple myeloma	0.461	0.539	0.000
E15-E16 Other disorders of glucose regulation and pancreatic internal secretion	0.171	0.539	0.290
L57 Skin changes due to chronic exposure to nonionising radiation	0.457	0.543	0.000
I20.8 Other forms of angina pectoris	0.457	0.543	0.000
E78.8 Other disorders of lipoprotein metabolism	0.454	0.546	0.000
# Top node	0.453	0.547	0.000
L57.0 Actinic keratosis	0.453	0.547	0.000
C30-C39 Malignant neoplasms of respiratory and intrathoracic organs	0.449	0.551	0.000
F60-F69 Disorders of adult personality and behaviour	0.448	0.552	0.000
C83 Diffuse non-Hodgkin's lymphoma	0.445	0.554	0.001
D83.8 Other common variable immunodeficiencies	0.000	0.555	0.444
D83.2 Common variable immunodeficiency with autoantibodies to B- or T-cells	0.000	0.555	0.444
D83.1 Common variable immunodeficiency with predominant immunoregulatory T-cell disorders	0.000	0.555	0.444
D83.0 Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function	0.000	0.555	0.444
F44 Dissociative [conversion] disorders	0.444	0.556	0.000
D84.8 Other specified immunodeficiencies	0.000	0.558	0.441
D84.1 Defects in the complement system	0.000	0.558	0.441
D84.0 Lymphocyte function antigen-1 [LFA-1] defect	0.000	0.558	0.441
L43.3 Subacute (active) lichen planus	0.437	0.563	0.000
L43.2 Lichenoid drug reaction	0.437	0.563	0.000
L43.1 Bullous lichen planus	0.437	0.563	0.000
L43.0 Hypertrophic lichen planus	0.437	0.563	0.000
F60 Specific personality disorders	0.437	0.563	0.000
F41.1 Generalised anxiety disorder	0.436	0.564	0.000
F43 Reaction to severe stress, and adjustment disorders	0.435	0.565	0.000
C90.1 Plasma cell leukaemia	0.435	0.565	0.000
C02.1 Border of tongue	0.434	0.566	0.000
C43 Malignant melanoma of skin	0.432	0.568	0.000
Chapter XVII Congenital malformations, deformations and chromosomal abnormalities	0.432	0.568	0.000
C86.6 Primary cutaneous CD30-positive T-cell proliferations	0.432	0.568	0.000
C86.5 Angioimmunoblastic T-cell lymphoma	0.432	0.568	0.000
C86.4 Blastic NK-cell lymphoma	0.432	0.568	0.000
C86.3 Subcutaneous panniculitis-like T-cell lymphoma	0.432	0.568	0.000
C86.2 Enteropathy-type (intestinal) T-cell lymphoma	0.432	0.568	0.000
C86.1 Hepatosplenic T-cell lymphoma	0.432	0.568	0.000
C86.0 Extranodal NK/T-cell lymphoma, nasal type	0.432	0.568	0.000
C94.7 Other specified leukaemias	0.432	0.568	0.000
C94.6 Myelodysplastic and myeloproliferative disease, not elsewhere classified	0.432	0.568	0.000
C94.5 Acute myelofibrosis	0.432	0.568	0.000
C94.4 Acute panmyelosis	0.432	0.568	0.000
C94.3 Mast cell leukaemia	0.432	0.568	0.000
C94.2 Acute megakaryoblastic leukaemia	0.432	0.568	0.000
C94.1 Chronic erythraemia	0.432	0.568	0.000
C94.0 Acute erythraemia and erythroleukaemia	0.432	0.568	0.000
C96.9 Malignant neoplasms of lymphoid, haematopoietic and related tissue, unspecified	0.432	0.568	0.000
C96.8 Histiocytic sarcoma	0.432	0.568	0.000
C96.7 Other specified malignant neoplasms of lymphoid, haematopoietic and related tissue	0.432	0.568	0.000
C96.6 Unifocal Langerhans-cell histiocytosis	0.432	0.568	0.000
C96.5 Multifocal and unisystemic Langerhans-cell histiocytosis	0.432	0.568	0.000
C96.4 Sarcoma of dendritic cells (accessory cells)	0.432	0.568	0.000
C96.3 True histiocytic lymphoma	0.432	0.568	0.000
C96.2 Malignant mast cell tumour	0.432	0.568	0.000
C96.1 Malignant histiocytosis	0.432	0.568	0.000
C96.0 Letterer-Siwe disease	0.432	0.568	0.000
D00-D09 In situ neoplasms	0.431	0.569	0.000
D58 Other hereditary haemolytic anaemias	0.000	0.569	0.430
C91 Lymphoid leukaemia	0.429	0.570	0.001
C90.2 Plasmacytoma, extramedullary	0.426	0.574	0.000
D53.8 Other specified nutritional anaemias	0.000	0.577	0.423
D53.2 Scorbutic anaemia	0.000	0.577	0.423
D53.1 Other megaloblastic anaemias, not elsewhere classified	0.000	0.577	0.423
D53.0 Protein deficiency anaemia	0.000	0.577	0.423
I22.8 Subsequent myocardial infarction of other sites	0.423	0.577	0.000
C90.3 Solitary plasmacytoma	0.420	0.580	0.000
Chapter IX Diseases of the circulatory system	0.419	0.581	0.000
D04 Carcinoma in situ of skin	0.418	0.582	0.000
C75 Malignant neoplasm of other endocrine glands and related structures	0.416	0.584	0.000
C32 Malignant neoplasm of larynx	0.414	0.586	0.000
F60.3 Emotionally unstable personality disorder	0.414	0.586	0.000
C93.9 Monocytic leukaemia, unspecified	0.410	0.589	0.000
C93.7 Other monocytic leukaemia	0.410	0.589	0.000
C93.3 Juvenile myelomonocytic leukaemia	0.410	0.589	0.000
C93.2 Subacute monocytic leukaemia	0.410	0.589	0.000
C93.0 Acute monocytic leukaemia	0.410	0.589	0.000
F44.9 Dissociative [conversion] disorder, unspecified	0.410	0.590	0.000
Q80-Q89 Other congenital malformations	0.410	0.590	0.000
F43.0 Acute stress reaction	0.407	0.593	0.000
C40-C41 Malignant neoplasms of bone and articular cartilage	0.407	0.593	0.000
L41.9 Parapsoriasis, unspecified	0.406	0.593	0.000
L41.8 Other parapsoriasis	0.406	0.593	0.000
L41.5 Retiform parapsoriasis	0.406	0.593	0.000
L41.4 Large plaque parapsoriasis	0.406	0.593	0.000
L41.3 Small plaque parapsoriasis	0.406	0.593	0.000
L41.2 Lymphomatoid papulosis	0.406	0.593	0.000
L41.1 Pityriasis lichenoides chronica	0.406	0.593	0.000
L41.0 Pityriasis lichenoides et varioliformis acuta	0.406	0.593	0.000
L44.9 Papulosquamous disorder, unspecified	0.406	0.593	0.000
L44.8 Other specified papulosquamous disorders	0.406	0.593	0.000
L44.4 Infantile papular acrodermatitis [Giannotti-Crosti]	0.406	0.593	0.000
L44.3 Lichen ruber moniliformis	0.406	0.593	0.000
L44.2 Lichen striatus	0.406	0.593	0.000
L44.1 Lichen nitidus	0.406	0.593	0.000
L44.0 Pityriasis rubra pilaris	0.406	0.593	0.000
C83.3 Large cell (diffuse)	0.406	0.594	0.000
L43.8 Other lichen planus	0.405	0.595	0.000
Q50-Q56 Congenital malformations of genital organs	0.405	0.595	0.000
C12 Malignant neoplasm of pyriform sinus	0.403	0.597	0.000
D59.8 Other acquired haemolytic anaemias	0.000	0.597	0.402
D59.6 Haemoglobinuria due to haemolysis from other external causes	0.000	0.597	0.402
D59.5 Paroxysmal nocturnal haemoglobinuria [Marchiafava-Micheli]	0.000	0.597	0.402
D59.4 Other nonautoimmune haemolytic anaemias	0.000	0.597	0.402
D59.3 Haemolytic-uraemic syndrome	0.000	0.597	0.402
D59.2 Drug-induced nonautoimmune haemolytic anaemia	0.000	0.597	0.402
D59.0 Drug-induced autoimmune haemolytic anaemia	0.000	0.597	0.402
E40-E46 Malnutrition	0.173	0.598	0.229
D56 Thalassaemia	0.000	0.601	0.399
C44.1 Skin of eyelid, including canthus	0.398	0.602	0.000
F48 Other neurotic disorders	0.395	0.605	0.000
D60-D64 Aplastic and other anaemias	0.000	0.605	0.395
C06 Malignant neoplasm of other and unspecified parts of mouth	0.394	0.606	0.000
M05-M14 Inflammatory polyarthropathies	0.394	0.606	0.000
E78.1 Pure hyperglyceridaemia	0.393	0.607	0.000
C13 Malignant neoplasm of hypopharynx	0.386	0.614	0.000
C64-C68 Malignant neoplasms of urinary tract	0.386	0.614	0.000
C32.0 Glottis	0.384	0.616	0.000
D83.9 Common variable immunodeficiency, unspecified	0.000	0.618	0.382
C93.1 Chronic monocytic leukaemia	0.380	0.619	0.000
C74.9 Adrenal gland, unspecified	0.380	0.620	0.000
D59.9 Acquired haemolytic anaemia, unspecified	0.000	0.621	0.379
C74.0 Cortex of adrenal gland	0.379	0.621	0.000
T39.1 4-Aminophenol derivatives	0.377	0.623	0.000
F41.3 Other mixed anxiety disorders	0.376	0.624	0.000
D84.9 Immunodeficiency, unspecified	0.000	0.625	0.375
D04.4 Skin of scalp and neck	0.375	0.625	0.000
F00-F09 Organic, including symptomatic, mental disorders	0.374	0.626	0.000
C05 Malignant neoplasm of palate	0.371	0.629	0.000
D80.9 Immunodeficiency with predominantly antibody defects, unspecified	0.000	0.629	0.371

This table lists the top 500 terms ordered by p(effect).

The full results table can be downloaded from this page.

The TreeWAS Database is the result of research conducted at the Oxford Big Data Institute at the University of Oxford.

This research has been conducted using the UK Biobank Resource (application number 10625). This work uses data provided by patients and collected by the NHS as part of their care and support.

This research has been conducted with the support of the Wellcome Trust (100956/Z/13/Z and 090532/Z/09/Z and 100308/Z/12/Z), the Danish National Research Foundation, Takeda, the Medical Research Council (MC_UU_12010/3), the Oak Foundation (OCAY-15-520), the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), the Wellcome Trust/Royal Society (204290/Z/16/Z) and the Li Ka Shing Foundation.

Variant-specific associations